This is a repository copy of The production and responsiveness to skin interferon (IFNλ1) are regulated by TNF-α.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/107497/

Version: Accepted Version

Proceedings Paper:

https://doi.org/10.1016/j.jid.2016.06.431

© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
The production and responsiveness to skin interferon (IFNλ1) are regulated by TNF-α

A. Alase, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

M. Stacey, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom

M. Goodfield, Department of Dermatology, University of Leeds, Leeds, United Kingdom

M. Wittmann Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

IL-29 (IFNλ1) is a type III IFN that is highly expressed in lesional skin of lupus patients. IL-29 is produced mainly by tissue cells and cutaneous responsiveness to the cytokine is most pronounced in keratinocytes. TNF alpha (TNF-α) is well known to be highly expressed in inflamed tissue. As such, biologics targeting TNF-α have proved extremely successful in treating psoriasis and other inflammatory diseases. However, TNF-α also has major regulatory functions. It is well known to counter-regulate the expression of type I interferons (IFNα/β). The effects of TNF-α on IL-29 is not well understood but of clinical relevance regarding patients who fail to respond to, or develop cutaneous side effects in the context of TNF blocking therapies. We here demonstrate, that TNF-α potently regulates the biological function and expression of IL-29 in the skin compartment. In cultured, human adult skin-derived fibroblasts and keratinocytes, TNF-α failed to induce the expression of IL-29 on its own or in combination with nucleic acids known to induce antiviral responses. Furthermore, IFN-γ dependent induction of the receptor for IL-29, IL-28R, was abrogated in the presence of TNF-α, causing a significantly reduced functional responsiveness of these cells with regard to anti-viral molecules expression, including MxA, GBP-1 and IFI16. In addition, TNF had a profound inhibitory effect on IL-29 expression by human fibroblasts in both non-stimulated or IFNα stimulated cells. Patients receiving anti-TNF therapy in form of infliximab or adalimumab showed increased plasma concentration of IL-29 under anti-TNF therapy. Our project demonstrates that IL-29 mediated anti-viral response by keratinocytes and fibroblasts is abrogated in the presence of TNF-α. Anti-TNF therapy increases systemic levels of IL-29. Further investigation is necessary to correlate IL-29 to different therapeutic responses or cutaneous side effects under anti-TNF therapy.